The first Fulvestrant in Europe approved for storage at room temperature.

Fulvestrant EVER Pharma is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

  • not previously treated with endocrine therapy
  • or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy

In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy

  • No special requirement for storage at 2°C-8°C - save on refrigerated storage space
  • No cold chain transportation - save on transport costs
  • Complete with high quality BD SafetyGlide™ Shielding Hypodermic Needle
  • Available as either a single or double pack

Visit our website: www.evervalinject.com